Formulation Development
Vetter Earns Prestigious Honors Across All Core Categories in the 13th Annual CDMO Leadership Awards
Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma,…
Intravacc Announces Positive Data of First in Human Intranasal OMV-Based Vaccine for SARS-CoV-2
Intravacc recently announced positive clinical data of a first in human (FIH) study of Avacc 10, an intranasal outer membrane vesicles (OMV) based booster vaccine…
Teva UK & Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalized Medicines
Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalized medicine. Under the agreement, Closed Loop Medicine and Teva UK will investigate….
Nanoscope Therapeutics Announces Positive Top-line Results From Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa
Nanoscope Therapeutics Inc. recently announced positive top-line results after the completion of the 2-year Phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010,…
Exothera Pledges to Fast-Track RNA Therapies With Expansion of World-First Continuous-Batch RNA Manufacturing Solution Into North America
Game-changing continuous-batch production of RNA service removes process development and scale-up steps through automation and significantly cuts clinical development time, while enhancing quality and yield….
Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy in Patients with Rare Inherited Retinal Disease LCA5
Opus Genetics recently announced the first cohort has completed dosing in its open-label, dose-escalation Phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an…
Bio-Rad Launches Validated Antibodies for Rare Cell & Circulating Tumor Cell Enumeration
Bio-Rad Laboratories, Inc. recently announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect…
Verge Genomics & Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy
Verge Genomics and Ferrer recently announced a strategic collaboration to co-develop VRG50635, Verge’s lead drug candidate, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis….
Imbria Pharmaceuticals Presents Results From IMPROVE-HCM Trial of Ninerafaxstat
Imbria Pharmaceuticals, Inc. recently announced the results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat, a novel cardiac mitotrope and partial fatty acid oxidation…
TFF Pharmaceuticals Announces Interim Data From Phase 2 Study of Tacrolimus Inhalation Powder
TFF Pharmaceuticals, Inc. recently announced the acceptance of its late-breaking clinical science abstract for oral presentation at the 44th Annual International Society for Heart and…
Bluejay Announces Receipt of PRIME Designation From EMA for Chronic Hepatitis Delta Virus Infection Treatment
Bluejay Therapeutics, Inc. recently announced the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to BJT-778 for the treatment of Chronic Hepatitis Delta…
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
IGC Pharma, Inc. recently announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in…
Pace Life Sciences Adds Liquid Capsule Filling Technology, Acquires New Jersey Laboratory From Curia & Appoints Dawn Von Rohr as Division President
Pace Life Sciences makes three major announcements for expansion of services, key acquisition, and new division Vice President….
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits From Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
Nykode Therapeutics ASA recently announced key conclusions from the updated analysis from the Phase 2 VB-C-02 trial. The trial investigates the use of Nykode’s wholly…
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study for Potential First-in-Class Therapeutic for Urea Cycle Disorders
Lead program in urea cycle disorders highlights power of CAMP4’s RAP Platform to increase gene expression using programmable, targeted medicines, with clinical candidate moving from screen-to-clinic within 3 years….
Lisata Therapeutics Announces US FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Lisata Therapeutics, Inc. recently announced the US FDA has granted Rare Pediatric Disease Designation (RPDD) to LSTA1, the company’s lead product candidate, for the treatment…
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
SciSparc Ltd. recently announced MitoCareX Bio Ltd., the company’s venture with Dr. Alon Silberman that focuses on drug discovery and the development of cancer therapeutics…
Bayer & Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines
Bayer AG and Thermo Fisher Scientific Inc. recently announced they will develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients…
Orchard Therapeutics Outlines US Launch Plans for the Only Approved Therapy for Children With Early Onset Metachromatic Leukodystrophy
Orchard Therapeutics recently announced the details of its US commercial launch of Lenmeldy (atidarsagene autotemcel), formerly known as OTL-200, the first FDA-approved therapy for the….
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Immix Biopharma, Inc. recently announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial. “We are…
